Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 20;10(8):ofad383. doi: 10.1093/ofid/ofad383

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 2. — Unadjusted Clostridioides difficile Health-related Quality-of-Life Survey (Cdiff32) scores (range, 0–100) during the blinded treatment period, stratified by treatment (modified intention-to-treat population, as-observed data) among all patients. A, Total score. B–D, Domain scores. The numbers of patients at baseline and at weeks 1, 4, and 8, were 176, 169, 136, and 129, respectively, for the RBL (fecal microbiota, live-jslm [REBYOTA; Rebiotix]) arm and 85, 76, 61, and 57 for the placebo arm.